Collegium Pharmaceutical Inc

Collegium’s modest insider sell‑off coincides with a $650 M acquisition of AZSTARYS—an opportunity for milestone cash flows, cross‑selling synergies, and future revenue growth.

Collegium insider sale shows a measured risk‑management move while its CNS & respiratory pipeline gains FDA fast‑track status, signaling potential upside once milestones hit.